Fatty Acid and PEA Mixture for Inflammatory Pathology Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory conditions such as rheumatoid arthritis, chronic ulcerous colitis, and autoimmune diseases like systemic lupus erythematosus have significant side effects due to their impact on the body's homeostatic systems and immune response, and dietary strategies alone are insufficient to manage chronic inflammation.
Innovation Solution
A mixture of specific fatty acids, including palmitic acid, oleic acid, stearic acid, linoleic acid, and palmitoylethanolamide, is used to effectively control the inflammatory process by regulating cell receptor activity, reducing the need for degranulation and minimizing side effects associated with traditional treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional treatments (corticosteroids and NSAIDs) are used to control inflammatory processes, then inflammatory conditions are effectively treated, but significant side effects occur due to impact on homeostatic systems and immune response
Solution Approach 1:
The patent introduces palmitoylethanolamide (PEA) as an intermediary substance that mediates the anti-inflammatory effect. PEA acts as a endogenous ligand for GPR55 receptors, preventing mast cell degranulation and reducing pro-inflammatory cytokine release, thereby controlling inflammation without the harmful side effects of traditional corticosteroids and NSAIDs
Solution Approach 2:
The patent changes the biochemical parameter by using specific fatty acid compositions (including PEA, linoleic acid, alpha-linolenic acid, and their ratios) to modulate the inflammatory response. The mixture of fatty acids with specific proportions alters the biological activity to achieve anti-inflammatory effects through receptor modulation rather than broad immunosuppression
2Ease of operation
If dietary strategies are used to manage chronic inflammation, then natural approach is taken, but they are insufficient to effectively manage chronic inflammation
Solution Approach 1:
The patent creates a composite therapeutic formulation combining multiple fatty acids (PEA, linoleic acid, alpha-linolenic acid) in specific ratios. This composite mixture synergistically enhances the anti-inflammatory effect compared to single fatty acid supplements, providing sufficient efficacy for chronic inflammation management while maintaining a natural biochemical approach
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mixture provides rapid and efficient control of inflammatory processes with reduced energy expenditure by cells, restoring physiological conditions without the adverse effects seen with corticosteroids and NSAIDs, effectively managing chronic and autoimmune inflammatory diseases.
Implementation Method 1
controlling the inflammatory process by regulating cell receptor activity, reducing the need for degranulation
Data Source
Figure 1
Figure 2
AI summary
The present invention relates to a mixture containing up to two fatty acids selected from palmitic acid, oleic acid, stearic acid, lino!eic acid, alpha-linolenic acid, gamma-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, azelaic acid and myristic acid and palmitoylethanolamide. In one embodiment of the present invention said mixture is characterized in that at least one of said up to two fatty acids is saturated. The present invention also relates to the use of the aforesaid mixture in the treatment of inflammatory and allergic pathologies.